PharmaGap raises additional funding

OTTAWA – Cancer drug developer PharmaGap raises gross proceeds of $114,720 in a private placement of 717,000 equity units (one common share and a PharmaGap-cropped.JPGwarrant to buy another) for $0.16 per unit. Warrants have a two year term and an exercise price of $0.20 per share. These terms mirror those of the private placement announced on June 17. The two placements total approximately $976,000. Proceeds from the latest placement will be used to advance PharmaGap’s portfolio of drug compounds and for general working capital.

Submit a comment

Please leave your name, which will be used to sign your submission to the SCANsite. Thanks for contributing your thoughts. Come back again. Tony Patterson, Editor & CEO.

© 2006 - 2009 SCAN
INTEGRITY INTELLIGENCE INFORMATION
Site by Citadel Rock
SCAN